Table 3.
Serum levels of 25OHD, calcium, PTH, and metabolic characteristics prior to and following the 12-week intervention.
| Placebo (n = 13) | Vitamin D (n = 10) | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Baseline | 12 weeks | Change | Baseline | 12 weeks | Change | |
| 25OHD (ng·mL−1) | 18.1 ± 6.5 | 23.5 ± 6.0 | 5.5 ± 7.9 | 20.8 ± 8.3 | 33.4 ± 7.2a | 12.3 ± 8.4 |
| Calcium (mmol·L−1) | 22.0 ± 0.9 | 21.8 ± 0.7 | −0.2 ± 0.7 | 22.5 ± 0.8 | 22.5 ± 0.6 | 0.0 ± 0.8 |
| PTH (pg·mL−1) | 43.2 ± 34.6 | 43.5 ± 29.8 | 0.3 ± 8.9 | 36.1 ± 10.7 | 24.0 ± 12.0a | −11.7 ± 10.6b |
| Fasting Glucose (mmol·L−1) | 5.3 ± 0.4 | 5.2 ± 0.4 | −0.1 ± 0.7 | 5.4 ± 0.5 | 5.1 ± 0.4 | −0.3 ± 0.6 |
| 2h Post-load Glucose (mmol·L−1) | 5.4 ± 1.2 | 5.5 ± 1.1 | 0.4 ± 1.4 | 6.2 ± 1.7 | 6.3 ± 1.7 | −0.1 ± 1.1 |
| Fasting Insulin (pmol·L−1) | 105.8 ± 71.2 | 114.9 ± 46.2 | −2.5 ± 44.1 | 108.5 ± 62.3 | 124.3 ± 69.5 | 13.6 ± 42.2 |
| AUCglucose (mmol·L−1·2 h−1) | 409.9 ± 82.9 | 391.9 ± 56.9 | −18.0 ± 63.4 | 447.7 ± 112.1 | 422.0 ± 95.7 | −25.7 ± 31.1 |
| HOMA-IR | 3.6 ± 2.4 | 3.9 ± 1.5 | −0.2 ± 1.7 | 3.8 ± 2.3 | 4.1 ± 2.3 | 0.2 ± 1.6 |
All values are means ± SDs.
a
Significantly different from baseline (P<0.05);
b
Significant group difference (P<0.05).
25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone; AUCglucose, area under the glucose curve; HOMA-IR, homeostatic model assessment of insulin resistance.